Latest News - ADU won't be approved

"Alzheimer's treatment is a huge, urgent, unmet need. But I also think that if we approved something where the data is not strong, that we have a risk of delaying an effective treatment for more than a couple of years," said one of the panelists, Joel Perlmutter, a professor of radiology and neuroscience at the Washington University School of Medicine.

"I think there's a huge danger in approving something that turns out not to be effective," he added.

 

He needs to be investigated as some say he is planning on leaving FDA and going into industry?

 

Alzheimer’s Association should reveal financial conflict of interest in urging FDA to approve Biogen drug, says Dr. Leslie Norins, CEO of Alzheimer’s Germ Quest

 

We should know more on Mach 21st 2021 until then keep up the great work with your profiling.

 

Profile my ass. This drug has no chance of approval. I’m budding up the resume and going to double dip like I did at my last company if I find something before the layoffs begin